S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover

Pfizer (PFE) Competitors

$27.76
+0.21 (+0.76%)
(As of 02/23/2024 ET)

PFE vs. BMY, ZTS, ABBV, MRK, JNJ, SNY, AZN, VRTX, REGN, and NVS

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Bristol-Myers Squibb (BMY), Zoetis (ZTS), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Sanofi (SNY), AstraZeneca (AZN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Novartis (NVS). These companies are all part of the "pharmaceutical preparations" industry.

Pfizer vs.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.

75.0% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 68.1% of Pfizer shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bristol-Myers Squibb currently has a consensus price target of $61.17, suggesting a potential upside of 18.40%. Pfizer has a consensus price target of $36.88, suggesting a potential upside of 32.84%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Pfizer is more favorable than Bristol-Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol-Myers Squibb
1 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.11
Pfizer
0 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 4.6%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 6.1%. Bristol-Myers Squibb pays out 62.2% of its earnings in the form of a dividend. Pfizer pays out 466.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol-Myers Squibb has increased its dividend for 15 consecutive years and Pfizer has increased its dividend for 14 consecutive years.

Bristol-Myers Squibb has a net margin of 17.83% compared to Bristol-Myers Squibb's net margin of 3.62%. Pfizer's return on equity of 50.95% beat Bristol-Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol-Myers Squibb17.83% 50.95% 16.67%
Pfizer 3.62%10.61%5.01%

In the previous week, Pfizer had 11 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 37 mentions for Pfizer and 26 mentions for Bristol-Myers Squibb. Bristol-Myers Squibb's average media sentiment score of 0.57 beat Pfizer's score of 0.49 indicating that Pfizer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol-Myers Squibb
13 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pfizer
19 Very Positive mention(s)
6 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Bristol-Myers Squibb has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Pfizer received 409 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. Likewise, 69.07% of users gave Pfizer an outperform vote while only 67.04% of users gave Bristol-Myers Squibb an outperform vote.

CompanyUnderperformOutperform
Bristol-Myers SquibbOutperform Votes
1076
67.04%
Underperform Votes
529
32.96%
PfizerOutperform Votes
1485
69.07%
Underperform Votes
665
30.93%

Bristol-Myers Squibb has higher earnings, but lower revenue than Pfizer. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$45.01B2.32$8.03B$3.8613.38
Pfizer$58.50B2.68$2.12B$0.3677.11

Summary

Pfizer beats Bristol-Myers Squibb on 12 of the 21 factors compared between the two stocks.


Get Pfizer News Delivered to You Automatically

Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFE vs. The Competition

MetricPfizerPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$156.74B$6.70B$5.19B$17.64B
Dividend Yield6.07%2.66%2.85%3.57%
P/E Ratio77.1117.75243.4124.84
Price / Sales2.681,204.743,354.097.33
Price / Cash10.2016.5299.7917.54
Price / Book1.624.554.406.10
Net Income$2.12B$149.04M$115.30M$870.05M
7 Day Performance0.51%1.07%0.88%-0.34%
1 Month Performance1.06%9.45%7.02%1.85%
1 Year Performance-33.51%4.11%10.09%89.27%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol-Myers Squibb
4.778 of 5 stars
$49.86
flat
$61.17
+22.7%
-26.4%$100.83B$45.01B12.9234,100Analyst Downgrade
ZTS
Zoetis
4.8329 of 5 stars
$186.66
-0.9%
$223.78
+19.9%
+18.6%$85.47B$8.54B36.8214,100Analyst Downgrade
ABBV
AbbVie
4.848 of 5 stars
$175.74
-1.0%
$175.36
-0.2%
+16.6%$316.33B$54.32B64.3750,000Insider Selling
Analyst Revision
MRK
Merck & Co., Inc.
4.7972 of 5 stars
$127.37
-0.3%
$129.68
+1.8%
+17.8%$322.76B$60.12B909.7969,000Analyst Revision
Positive News
JNJ
Johnson & Johnson
4.8744 of 5 stars
$157.86
+0.8%
$176.14
+11.6%
+3.8%$380.01B$85.16B11.43155,800Analyst Report
SNY
Sanofi
3.5999 of 5 stars
$46.85
+1.5%
$57.50
+22.7%
+2.2%$118.51B$46.61B19.8591,573Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
AZN
AstraZeneca
3.5451 of 5 stars
$65.04
+1.2%
$80.00
+23.0%
-0.8%$201.65B$45.81B33.8883,500Gap Up
VRTX
Vertex Pharmaceuticals
4.413 of 5 stars
$420.64
-0.4%
$417.27
-0.8%
+49.7%$108.66B$9.87B30.285,400Analyst Report
Insider Selling
REGN
Regeneron Pharmaceuticals
4.0651 of 5 stars
$946.87
-0.1%
$939.05
-0.8%
+29.6%$103.29B$13.12B27.2513,450
NVS
Novartis
2.2619 of 5 stars
$102.74
+2.5%
$99.50
-3.2%
+21.4%$217.77B$45.44B14.3176,057Analyst Report
Gap Up

Related Companies and Tools

This page (NYSE:PFE) was last updated on 2/25/2024 by MarketBeat.com Staff